Ghost Tree Capital, LLC Protagonist Therapeutics, Inc Transaction History

Ghost Tree Capital, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$21.79 - $32.15 $1.09 Million - $1.61 Million	-50,000 Reduced 40.0%	75,000 $2.17 Million
Q4 2023 Feb 14, 2024	SELL	$14.05 - $23.44 $3.86 Million - $6.45 Million	-275,000 Reduced 68.75%	125,000 $2.87 Million
Q3 2023 Nov 14, 2023	BUY	$16.68 - $23.66 $2.92 Million - $4.14 Million	175,000 Added 77.78%	400,000 $6.67 Million
Q1 2023 May 15, 2023	BUY	$10.78 - $25.38 $2.43 Million - $5.71 Million	225,000 New	225,000 $5.18 Million
Q2 2020 Aug 14, 2020	SELL	$6.19 - $18.84 $1.41 Million - $4.29 Million	-227,827 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$5.4 - $9.22 $254,734 - $434,935	-47,173 Reduced 17.15%	227,827 $1.61 Million
Q4 2019 Feb 14, 2020	BUY	$4.69 - $13.45 $117,250 - $336,250	25,000 Added 10.0%	275,000 $1.94 Million
Q3 2019 Nov 14, 2019	BUY	$9.41 - $16.56 $470,500 - $827,999	50,000 Added 25.0%	250,000 $3 Million
Q2 2019 Aug 14, 2019	SELL	$8.98 - $12.96 $4.49 Million - $6.48 Million	-500,000 Reduced 71.43%	200,000 $2.42 Million
Q1 2019 May 15, 2019	BUY	$6.5 - $13.77 $4.55 Million - $9.64 Million	700,000 New	700,000 $8.8 Million

247

56.4M

76.3K

114K

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $2B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

Get notified when there are updates to the investment portfolio of Ghost Tree Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ghost Tree Capital, LLC with notifications on news.